Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma

NCT00003605 is registered in ClinicalTrials.gov with Hoag Memorial Hospital Presbyterian as lead sponsor.

NCT NCT00003605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma
Lead sponsor
Hoag Memorial Hospital Presbyterian
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 1998
Completion date
January 31, 2000
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma